ArticleBreast cancer (Dove Medical Press)2025
Ambra1 Deficiency Inhibits the Proliferation of Breast Cancer Cells Through the Akt-FoxO1-p27 Pathway.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The unlimited proliferation of breast cancer (BC) cells is the basis for recurrence and metastasis. Ambra1 is involved in the regulation of cell proliferation, but its role may be cancer type-dependent, and the underlying mechanisms need further exploration. In addition, it remains unclear whether Ambra1 is involved in regulating the proliferation of BC cells. This study aims to explore the regulatory effect of Ambra1 on the proliferation of BC cells, as well as the underlying mechanisms. Methods: The effects of Ambra1 on cell proliferation were detected in MCF-7 and MDA-MB-231 cells using CCK-8, EdU, and colony formation assays. The role of Ambra1 in regulating p27 via the Akt-FoxO1 pathway was determined in MCF-7, MDA-MB-231, and 293T cells through Western blotting, qRT-PCR, and co-immunoprecipitation. Subsequently, the role of p27 in Ambra1-mediated regulation of cell proliferation was validated in cell models and xenograft mouse models. Results: Ambra1 deficiency significantly inhibited the proliferation of BC cells. p27 played a crucial role in this process. Furthermore, Ambra1 regulates the phosphorylation of the Ser256 residue of FoxO1 through Akt, thereby altering the nuclear distribution of FoxO1 and the transcription of p27. Conclusion: Ambra1 can control the proliferation of BC cells by regulating the Akt-FoxO1-p27 signaling pathway. Therefore, this protein is a potential therapeutic target for BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.